글로벌 연구동향
방사선종양학
- 2023년 08월호
[Asia Pac J Clin Oncol .] Consolidative high-dose thoracic radiotherapy for limited metastatic nonsmall cell lung cancer: Focusing on oligo-progressive disease고려의대 / 김하경, 양대식*
- 출처
- Asia Pac J Clin Oncol .
- 등재일
- 2023 Jun
- 저널이슈번호
- 19(3):385-391. doi: 10.1111/ajco.13880. Epub 2022 Dec 4.
- 내용
Abstract
Aim: Prior clinical data have shown a significant survival benefit of consolidative local radiotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC). Therefore, this study aimed to evaluate the impact of consolidative high-dose thoracic radiotherapy on local control rates and survivals in patients with limited metastatic NSCLC, especially focusing on oligo-progressive disease.Methods: We retrospectively reviewed the medical records of 45 patients with limited metastatic NSCLC who received consolidative high-dose thoracic radiotherapy at the Korea University Guro Hospital between March 2015 and December 2020. In the current study, we included patients who showed partial response, stable disease, or oligo-progressive disease on tumor response evaluation after systemic treatment. All patients underwent stereotactic body radiation therapy (23 patients) or intensity-modulated radiation therapy (IMRT, 22 patients).
Results: The median follow-up time was 42 months (range: 5-88 months). The overall 2-year disease-free survival (DFS) and overall survival (OS) rates were 80.7% and 88.4%, respectively. Among the 45 patients, only two patients treated with IMRT showed in-field local recurrence. There was no local failure among the patients who showed oligo-progressive disease after systemic treatment. In addition, the response to systemic treatment was not a significant factor for either DFS or OS rates (p = .471 and p = .414, respectively) in univariate analysis.
Conclusions: Consolidative high-dose thoracic radiotherapy improves local control rates and helps achieve long-term survival in patients with limited metastatic NSCLC. It is also effective and should be considered in patients with oligo-progressive disease after systemic treatment.
Affiliation
Hakyoung Kim 1, Dae Sik Yang 1, Sun Myung Kim 1
1Department of Radiation Oncology, Korea University Guro Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
- 키워드
- local control; metastasis; nonsmall cell lung cancer; radiotherapy; survival.
- 덧글달기
- 이전글 [Yonsei Med J .] Short-Term Outcomes and Cost-Effectiveness between Long-Course Chemoradiation and Short-Course Radiotherapy for Locally Advanced Rectal Cancer
- 다음글 [Radiother Oncol .] Adjuvant radiotherapy in node-negative salivary malignancies of the parotid gland: A multi-institutional analysis
편집위원
일반적으로 전이성 폐암환자는 항암요법 단독으로 치료하게 되며 그 예후는 매우 나쁜 것으로 알려져 있음. 그러나 전이성 폐암환자 중 전이 병소 및 개수가 제한된 전이성 비소세포폐암(limited metastatic NSCLC) 환자에서 항암화학요법 후 공고 목적(consolidative)의 국소방사선치료가 생존향상에 도움이 된다는 보고들이 제기되고 있는데, 해당 연구는 이를 주제로 45명의 환자를 대상으로 후향적으로 분석했음. 2년 무병생존율과 전체생존율은 각각 80.7%와 88.4로 확인된 바, 제한된 전이성 비소세포폐암 환자나 oligo-progressive 환자에서 항암화학 요법 후 공고 목적의 국소방사선치료를 고려해 보아야 한다는 것을 강조함.
덧글달기닫기2023-08-08 13:58:55
등록